Methods for alzheimer's disease treatment and cognitive enhancement
AssigneeNeurologic, Inc.
InventorsRene Etcheberrigaray, Daniel L. Alkon
Life of this patent
Estimating the term…
Abstract
The present invention relates to compositions and methods to modulate α-secretase and/or to improve cognitive ability. The invention further relates the improved/enhanced cognitive ability in diseased individuals, particularly Alzheimer's Disease patients, and treatment thereof through increased sAPP production. Macrocyclic lactones (i.e. bryostatin class and neristatin class) are compounds preferred for use with the present composition. The present invention also provides methods for increasing the generation of non-amyloidogenic soluble APP comprising the activation of protein kinase C (PKC) by administering an effective amount of PKC activator(s).
Claims36
A method for enhancing cognitive ability in a human or animal, comprising administering to said human or animal a PKC activator in an amount effective for enhancing cognitive ability in a pharmaceutically acceptable carrier.
A method for altering cellular modulation of ion channels comprising administering a PKC activator in an amount effective for altering cellular modulation of ion channels and a pharmaceutically acceptable carrier.
A method for treating neurotumors comprising administering macrocyclic lactone in an amount effective to treat said neurotumors and a pharmaceutically acceptable carrier.
A method for modulating sAPP comprising administering a macrocyclic lactone in an amount effective to modulate sAPP and a pharmaceutically acceptable carrier.
A method for modulating α-secretase comprising administering a macrocyclic lactone in an amount effective to modulate a-secretase anda pharmaceutically suitable carrier.
A method for treating Alzheimer's Disease comprising administering to a patient a macrocyclic lactone in an amount effective to treat Alzheimer's Disease and a pharmaceutically acceptable carrier.
A method for treating Alzheimer's Disease comprising administering bryostatin-1 to a patient in an amount effective to treat Alzheimer's Disease and a pharmaceutically acceptable carrier.
A method for enhancing cognitive ability in a human or animal, comprising administering to said human or animal a bryostatin or a neristatin class compound in an amount effective for enhancing cognitive ability in a pharmaceutically acceptable carrier.
A method for enhancing cognitive ability in a human or animal, comprising administering to said human or animal bryostatin-1 in an amount effective for enhancing cognitive ability in a pharmaceutically acceptable carrier.
A method comprising the modulation of α-secretase through the administration of a pharmaceutically effective amount of a bryostatin or a neristatin class compound and a pharmaceutically acceptable carrier.
A method for modulating α-secretase comprising administering bryostatin-1 in an amount effective to modulate α-secretase and a pharmaceutically acceptable carrier.
A method for providing a neuroprotective effect for cell comprising administering a bryostatin or neristatin class compound in an amount effective to provided a neuroprotective effect for cells which suffer from a hypoxic event and a pharmaceutically acceptable carrier.
A method for providing a neuroprotective effect for cell comprising administering bryostatin-1 in an amount effective to provided a neuroprotective effect for cells which suffer from a hypoxic event and a pharmaceutically acceptable carrier.
A method for the reduction of amyloid plaque formation comprising administering bryostatin-1 in an amount effective to reduce amyloid plaque formation and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.